Business Context and Reporting Period
This Form 8-K is filed by Hancock Jaffe Laboratories, Inc. (not Envveno Medical Corp) for the reporting period of June 15, 2020. The filing addresses a critical corporate governance event regarding the company's continued listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric referenced is the regulatory threshold for stockholders' equity, which is $2.5 million under Nasdaq Listing Rule 5550(b).
Material Changes and Events
- Nasdaq Listing Extension Granted: On June 8, 2020, the Nasdaq Hearings Panel granted the company's request for an extension to demonstrate compliance with the minimum $2.5 million stockholders' equity requirement.
- Compliance Deadline: The company must evidence compliance by July 31, 2020.
- Previous Delisting Notice: The company had previously received notice on April 14, 2020, of potential delisting due to non-compliance with the equity requirement.
Outlook, Risks, and Management Commentary
Management states it is taking definitive steps to meet the compliance terms by the July 31, 2020 deadline. However, the filing explicitly notes there is no assurance that the company will achieve compliance by this date or that the Panel will grant a further extension if necessary. While the Panel has the discretion to grant an extension through October 12, 2020, such an extension is not guaranteed.
Investor Verification Checklist
- Verify the company's current stockholders' equity balance to assess proximity to the $2.5 million threshold.
- Monitor subsequent filings for confirmation of compliance by the July 31, 2020 deadline.
- Review the company's capitalization strategy to understand how it plans to raise the required equity.
- Confirm the trading status of common stock (HJLI) and warrants (HJLIW) on The NASDAQ Stock Market LLC.